|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021753,
umls-concept:C0021755,
umls-concept:C0063710,
umls-concept:C0231491,
umls-concept:C0332307,
umls-concept:C0597357,
umls-concept:C1145667,
umls-concept:C1510827,
umls-concept:C1533157,
umls-concept:C1709634,
umls-concept:C1709694,
umls-concept:C1749467
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1995-4-4
|
|
pubmed:abstractText |
Two IL-1 receptors have been identified, termed type I and type II. The extracellular domain of the type II IL-1 receptor is released from certain cells and can function as a specific inhibitor of IL-1 beta activity. We assessed the ligand-binding properties of the type II membrane-bound and soluble IL-1 receptor (sIL-1R) from the human B cell line Raji by competition. Upon release, the affinity of sIL-1R for IL-1 alpha and IL-1 beta remained constant, and both soluble and cell surface IL-1 receptors bound to the same regions on the IL-1 beta molecule as defined by binding of a series of IL-1 beta mutant molecules. However, the affinity of sIL-1R for the IL-1 receptor antagonist (IL-1ra) decreased by a factor of 2000 when compared with the cell surface receptor. Type II sIL-1R and IL-1ra had an additive effect in inhibiting the binding of IL-1 beta to cell surface IL-1 receptors. In contrast, the combination of recombinant type 1 sIL-1R with IL-1ra abrogated the inhibition seen with each of the individual agents alone. The type II cell surface IL-1 receptor failed to bind the biologically inactive IL-1 beta precursor molecule, but binding to the IL-1 beta precursor was observed on cellular release of the receptor; this was confirmed with 35S-labeled IL-1 beta. Binding of IL-1 beta precursor by sIL-1R inhibited the precursor's ability to be processed to the mature, biologically active 17-kDa species. These observations suggest that the type II sIL-1R inhibits IL-1 beta at two steps, by preventing processing of propeptide and by blocking the interaction of mature IL-1 beta with type I IL-1 receptor. In addition, type II sIL-1R does not interfere with inhibition mediated by IL-1ra.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1339309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1373520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1386364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1394428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1574116,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1633262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1699802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1826616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1830582,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1833184,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1834761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-1837145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2137098,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2137200,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2145273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2151765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2156847,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2182393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2524527,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2787507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2950091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2955410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-2969618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-3049798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-3259176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-3259579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-4202581,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-7683661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-8049450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-8327496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-8332913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7878046-8428929
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
28
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1714-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7878046-Humans,
pubmed-meshheading:7878046-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:7878046-Interleukin-1,
pubmed-meshheading:7878046-Mutagenesis, Site-Directed,
pubmed-meshheading:7878046-Protein Binding,
pubmed-meshheading:7878046-Protein Precursors,
pubmed-meshheading:7878046-Protein Processing, Post-Translational,
pubmed-meshheading:7878046-Receptors, Interleukin-1,
pubmed-meshheading:7878046-Sialoglycoproteins,
pubmed-meshheading:7878046-Solubility,
pubmed-meshheading:7878046-Structure-Activity Relationship,
pubmed-meshheading:7878046-Tumor Cells, Cultured
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.
|
|
pubmed:affiliation |
Department of Medicine, University of Sheffield, Royal Hallamshire Hospital, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
